COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Netupitant - Palonosetron Market Expected to Reach $527,187 Million, Globally, by 2022


quote Netupitant–Palonosetron FDC market holds a substantial scope for growth globally. The market, which is in its growth stage, however, is anticipated to contribute significantly to the global market within the next six years. quote

to Hemali Narkhede
Manager, Healthcare Research at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

Netupitant Palonosetron Market Report, published by Allied Market Research, was valued at $257,162 million in 2015, and is expected to reach $527,187 million by 2022, growing at a CAGR of 10.8% from 2016 to 2022.

Access Full Summary
at: https://www.alliedmarketresearch.com/netupitant-palonosetron-FDC-market

Netupitantpalonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years.
High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future.


  • North America dominated the netupitantpalonosetron market, and is expected to grow at a CAGR of 9.9%.

  • Asia-Pacific shows thehighestgrowthrate, and is estimated to grow at a CAGR of 14.7%.

Key players profiled in this report include Acacia Pharma, Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd.


Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Netupitant-Palonosetron FDC Market - Global Opportunity Analysis and Industry Forecast, 2014-2022 quote

View Report

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Netupitant - Palonosetron Market"
Purchase Enquiry